Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib
Marta A Miyares, Kyle DavisPharmacy Department, Jackson Memorial Hospital, Miami, FL, USAAbstract: Cardiovascular disease (CVD) is responsible for significant morbidity and mortality within the United States and worldwide. Although targeting low-density lipoprotein cholesterol (LDL-C) in the prevent...
Main Authors: | Miyares MA, Davis K |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2012-08-01
|
Series: | Vascular Health and Risk Management |
Online Access: | http://www.dovepress.com/patient-considerations-and-clinical-impact-of-cholesteryl-ester-transf-a10791 |
Similar Items
-
Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib
by: Goldberg AS, et al.
Published: (2012-09-01) -
How anacetrapib inhibits the activity of the cholesteryl ester transfer protein? Perspective through atomistic simulations.
by: Tarja Äijänen, et al.
Published: (2014-11-01) -
Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis.
by: Chuanwei Li, et al.
Published: (2013-01-01) -
Biochemical characterization of cholesteryl ester transfer protein inhibitors
by: Mollie Ranalletta, et al.
Published: (2010-09-01) -
Increased concentration of plasma cholesteryl ester transfer protein in nephrotic syndrome: role in dyslipidemia.
by: P Moulin, et al.
Published: (1992-12-01)